Introduction {#Sec1}
============

Glycated Hemoglobin A1c as a Marker of Glycemic Control {#Sec2}
-------------------------------------------------------

Identified in the mid-1960s, and subsequently recognized for its role in metabolic control, glycated hemoglobin A~1c~ (HbA1c) is the foremost indicator of blood glucose control \[[@CR1]\]. Its value in type 1 diabetes (T1D) and type 2 diabetes (T2D) was established in landmark studies, which showed that reducing HbA1c to close-to-normal levels decreases the risk of diabetes-related conditions (including short- and long-term microvascular complications such as retinopathy and neuropathy and long-term macrovascular diseases such as coronary artery disease and stroke) \[[@CR2]--[@CR7]\], hence the recommendations for its use as a measure of glycemic control \[[@CR8], [@CR9]\]. Standardized assays provide an easy, reliable, and relatively inexpensive means of obtaining HbA1c measurements \[[@CR10]\], which are familiar to both healthcare providers and patients \[[@CR1]\].

HbA1c measurement does, however, have limitations (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR13]\]. HbA1c values indicate the average glucose concentrations over a period of 8--12 weeks, so an HbA1c of 7%, for example, reflects an average glucose concentration of approximately 154 mg/dl (8.6 mmol/l), but may represent a range of 123--185 mg/dl (6.8 − 10.3 mmol/l), and this range broadens as HbA1c values increase \[[@CR14]\]. However, a broader range of 50--258 mg/dl (2.8--14.3 mmol/l) would also reflect an average of 154 mg/dl, but would indicate a very different glucose response during the measurement period. Moreover, HbA1c values give no indication of intra- or inter-day fluctuations in blood glucose \[[@CR15]\] or of episodes of hyperglycemia and hypoglycemia; patients with similar values can in fact have very different patterns of glycemic variability (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR15], [@CR16]\]. HbA1c can also be affected by factors unrelated to glycemia (e.g., conditions affecting erythrocyte turnover, iron deficiency, genetics, and race) \[[@CR17]\].Table 1Advantages and disadvantages of glucose monitoring techniques \[[@CR11]--[@CR13]\]AdvantagesDisadvantagesHbA1c- Easy to measure- Inexpensive to perform- Widely used and familiar- Standardized test- Only provides an approximate measure of glycemia over the previous 8--12 weeks- Does not reflect hypoglycemia, glycemic variability, or glucose excursions- Unreliable in certain conditions (e.g., renal failure, anemia)SMBG- Accurate measure of capillary glucose concentrations- Relatively inexpensive- Easy to train patients- Widely used and familiar- Subject to user error and misrecorded data- Requires training or checking- Provides limited data at a single point in time- Sporadic measurements limit clinical effectiveness- Multiple daily testing needed to effectively alter management and achieve good glycemic control (limited by patient tolerance)- Inconvenient and painful- Variable quality of glucose test strips (damaged or expired strips)CGM- Provides a comprehensive picture of variations in glucose levels, including at times when they would normally not be measured (e.g., while sleeping, during exercise)- No 'missed' readings- Provides a wide range of metrics to help guide and individualize diabetes management- Simple to use; sensor remains in place for several days- Pre-calibrated systems remove the need for daily fingersticks- More expensive than SMBG- Relatively complex to understand; requires training and time for familiarization- Needs high levels of compliance and interaction- Many models require multiple daily fingersticks for calibration with SMBG- Sensor is always on the body; requires regular replacement (every 3--14 days, depending on model)*CGM* continuous glucose monitoring, *HbA1c* glycated hemoglobin A~1c~, *SMBG* self-monitoring of blood glucoseFig. 1Differences in glycemic variability over 15 days for two patients with similar HbA1c levels. *BG* blood glucose, *GV* glycemic variability, *HbA1c* glycated hemoglobin A~1C~Reproduced from Kovatchev and Cobelli \[[@CR16]\] © 2016 by the American Diabetes Association

This article is based on previously conducted studies and does not contain any work performed by any of the authors with human participants or animals.

Self-Monitoring of Blood Glucose and Current Limitations {#Sec3}
--------------------------------------------------------

When the first blood glucose monitors for self-testing were developed in the early 1970s, concerns over their practicality, accuracy, and precision limited their use by patients \[[@CR18]\], but monitors are now compact and convenient, providing results in a few seconds from only 0.3--1 μl of blood \[[@CR15], [@CR18]\]. Self-monitoring of blood glucose (SMBG) is fast, relatively inexpensive, and generally accurate \[[@CR18]\], although low-cost meters and strips are usually less accurate and have higher lot-to-lot variability \[[@CR19]\].

SMBG facilitates self-management and the involvement of patients in care. SMBG results can guide patients on nutrition and exercise, hypoglycemia prevention, and adjustment of medication to individual circumstances \[[@CR8]\]. More frequent SMBG has been linked to lower HbA1c levels in patients with T1D \[[@CR20]\] and in insulin-treated patients with T2D \[[@CR21], [@CR22]\], but is believed to be of limited value in those patients with T2D who are not using insulin \[[@CR23]\]. Although SMBG frequency should be dictated by individual needs and goals, the American Diabetes Association recommends SMBG for most patients on intensive insulin regimens \[i.e., those using multiple doses or continuous subcutaneous insulin infusion (CSII), known as the insulin pump\] and further recommends its use to guide treatment decisions for patients on less-intensive regimens or noninsulin therapy \[[@CR8]\].

The limitations of SMBG (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR13]\] largely relate to its perceived intrusiveness: it requires fingersticks several times daily \[[@CR8]\], which can be time consuming, inconvenient, and painful, consequently leading to poor compliance \[[@CR24]\] and impaired quality of life. SMBG data can be misreported, often because manually entered data are accidentally or deliberately incorrect (e.g., to show favorable results or to hide hyperglycemia or hypoglycemia) \[[@CR25]--[@CR28]\]. Misreporting in clinical studies is often due to data entries that cannot be correlated with a corresponding meter reading \[[@CR28]\], and many physicians are familiar with logbooks that are filled out 'retrospectively' in the waiting room. Patients using SMBG need instruction and regular evaluation of their technique and use of their data to adjust therapy \[[@CR8]\], which is a time-consuming process for healthcare providers. Ultimately, SMBG can provide only a 'snapshot' of a patient's glycemic status at the time of sampling that, as for HbA1c, may not identify glucose excursions \[[@CR11], [@CR12]\].

Hypoglycemia {#Sec4}
------------

Attainment of near-normal HbA1c levels can be challenging for patients, largely because tightening glycemic control increases the risk of hypoglycemia \[[@CR8], [@CR9], [@CR29]\]. In a recent observational study, 97.4% of patients with T1D, and 78.3% of patients with T2D, had experienced hypoglycemia; this experience, and fear of future hypoglycemia episodes, may lead patients to eat defensively, restrict exercise, miss work or school, or skip insulin doses \[[@CR30]\]. Hypoglycemia, however, is not restricted to insulin use. Sulfonylureas are also associated with increased risk of hypoglycemia, particularly in older patients and those with significant renal insufficiency, which may raise questions regarding their use in these populations \[[@CR31], [@CR32]\]. Due to concerns regarding occurrence of hypoglycemia with sulfonylurea therapy, glucose testing is recommended, an additional burden that can limit the use of these agents.

Hypoglycemia negatively affects many aspects of a patient's quality of life. It is associated with inadequate glycemic control, injuries due to falls or accidents (including traffic accidents) \[[@CR8]\], and other serious complications. Long-term risks include diminished cognition (a particular concern for elderly patients) \[[@CR8]\] and increased cardiovascular morbidity \[[@CR33], [@CR34]\]. Recurrent hypoglycemia may also negatively affect cognitive performance in children with T1D and in adults with long-standing diabetes \[[@CR35], [@CR36]\], whereas severe hypoglycemia can lead to seizure, coma, or death \[[@CR8], [@CR37]--[@CR40]\] and has been linked to increased mortality in both clinical trials \[[@CR41], [@CR42]\] and in clinical practice \[[@CR39]\].

Fear of hypoglycemia is a major barrier to glycemic control as it results in reluctance to adhere to or intensify therapy and in avoidance strategies relating to food and exercise that can adversely affect glycemic management \[[@CR43]\]. However, recognition of hypoglycemia, especially if asymptomatic ('silent') or nocturnal, can be problematic \[[@CR44]\], particularly for patients who only sporadically test their glucose levels using SMBG.

Glycemic Variability {#Sec5}
--------------------

Glycemic variability, characterized by the amplitude, frequency, and duration of fluctuations in blood glucose, can be expressed in terms of standard deviation, mean amplitude of glucose excursions, and coefficient of variation (CV) (Table [2](#Tab2){ref-type="table"}) \[[@CR45]--[@CR47]\]. The CV is a measure of short-term within-day variability \[[@CR45]\]; generally, a value \< 36% defines stability, whereas a value ≥ 36% reflects instability with significantly increased risk of hypoglycemia \[[@CR47]\].Table 2Metrics used in CGMMetricsDefinitionAdvantages/limitationsStandard deviation \[[@CR45]\]A measure of variance of glucose levelsDirectly calculated by all devicesCoefficient of variation \[[@CR45]\]A measure of short-term within-day variability, independent of the mean value; percentiles represent deviations about the median, thus distinguishing stable from labile glycemic controlEasy to calculate from standard deviation and mean glucose levelMean amplitude of glucose excursions \[[@CR45]\]A measure of short-term within-day variabilityObtained indirectly, through calculationPrecision absolute relative deviation \[[@CR46]\]Indicates the similarity of two sensor traces simultaneously recorded from a single CGM system worn by one subjectEasy to compute and interpret, but lacks detailed informationContinuous glucose-error grid analysis \[[@CR46]\]Provides a clinical assessment of accuracy by comparing CGM and SMBG resultsReadings must be obtained at least every 15 minMean absolute relative difference \[[@CR47]\]Indicates the similarity of CGM and reference blood glucose results; expressed as the average of absolute errors between all CGM values and matched reference valuesProvides a single value that represents the overall accuracy of the CGM system*CGM* continuous glucose monitoring, *SMBG* self-monitoring blood glucose

In the short and medium term, wide glycemic variability is associated with adverse clinical outcomes (e.g., microvascular and macrovascular complications, increased mortality, and longer hospital stays) \[[@CR48]--[@CR50]\]. The extent of this variability has been associated with two different components of dysglycemia, namely chronic sustained hyperglycemia and acute dysglycemic fluctuations (peaks and nadirs). In the case of chronic sustained hyperglycemia, there is excessive and accelerated protein glycation, whereas in the case of acute dysglycemic fluctuations there is increased oxidative stress \[[@CR51]\].

Minimizing glycemic variability thus appears to be a sensible treatment goal alongside that of reducing glycemic burden as measured by HbA1c, but only recently has accurate and reliable measurement of glycemic variability become possible \[[@CR15], [@CR52]\]. Real-time measurement of glucose levels 24 h per day is possible using continuous glucose monitoring (CGM). While CGM was initially expected to revolutionize intensive insulin therapy, progress has been gradual, largely because of issues of cost and reliability, and difficulties in use, as well as lack of a standardized format for data display and uncertainty about the best use of the copious data \[[@CR53]\].

Technologic developments have made CGM devices easier to use, more reliable, and more cost effective; for example, some systems warn patients when blood glucose falls (or may fall) below or rises above set levels \[[@CR53]\]. Most manufacturers recommend frequent recalibration using capillary blood glucose meters and reagent strips to maintain sensor accuracy \[[@CR54]\]; failure to do so may result in inappropriate and risky treatment decisions.

The identification of the most clinically useful CGM metrics and the increased use of standardized, simplified data presentation allow the newer systems to provide clear and visual information upon which physicians and patients can base management decisions \[[@CR53]\].

Current Status of CGM {#Sec6}
---------------------

CGM can be considered an advance on SMBG (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR13]\]. It provides a comprehensive picture of glycemic variability and allows glucose fluctuations to be linked to events such as meals, exercise, sleep, and medication intake---information that can help guide diabetes management \[[@CR47]\].

CGM uses a fixed sensor with a subcutaneous, glucose-oxidase platinum electrode that measures glucose concentrations in the interstitial fluids \[[@CR13]\]. However, a time lag between the measurement and display of the result due to a physiologic delay (while glucose diffuses from the vascular space to the interstitial fluid) \[[@CR55], [@CR56]\] can adversely affect accuracy and hamper the detection of hypoglycemia, particularly during rapid changes. The delays are smaller in adolescents than in adults, increase with age, and differ between devices for the same subject \[[@CR56]\].

CGM devices either continuously track the glucose concentration and provide near real-time data or retrospectively show continuous measurements intermittently (i.e., when the user looks at the device). Intermittent devices include 'flash' systems, from which stored data can be uploaded at any time \[[@CR47]\]. Their overall high cost can be offset by patients having intermittent blinded glucose sensors with a single reader kept by the attending healthcare professional (termed 'professional' CGM systems). Data are not seen in real time but are downloaded after a set period \[[@CR57]\]; 14 days is the recommended period of time as this is the estimated minimum time of monitoring needed to obtain an accurate assessment of long-term glucose control \[[@CR58]\].

The advantage of real time over intermittent CGM is that it can warn users of impending hypoglycemia or hyperglycemia. Data may be masked/blinded (unavailable to the patient and retrospectively viewed by the physician) or unmasked/unblinded (available to the patient and remotely to physicians and caregivers, either in real time or retrospectively) \[[@CR47], [@CR59]\]. Although blinding may be preferred to avoid influencing patient behavior and to help understand patients' usual habits \[[@CR57]\], an unblinded system may facilitate improvements in glycemic variability and help patients avoid hypoglycemia and hyperglycemia \[[@CR60]\], and immediate feedback can help patients learn to manage the effects of food, exercise, and medication \[[@CR57]\]. Therefore, some healthcare providers argue that real-time CGM should replace blinded methodologies, noting that blinding can result in increased risk and potential for harm in cases of unrecognized severe hypoglycemic episodes \[[@CR12]\]; in addition, a retrospective evaluation of patients with T1D and TD2 using blinded CGM for 3 days did not show significant differences in pre- and post-study HbA1c levels \[[@CR61]\].

Regardless of its type, CGM provides a measure of the time for which blood glucose is within the target range ('time in range') \[70--180 mg/dl (3.9--10 mmol/l)\] and of the duration and severity of hypoglycemia; it can alert to low glucose at level 1 \[\< 54--70 mg/dl (3.0--3.9 mmol/l) with or without symptoms\], level 2 \[\< 54 mg/dl (3.0 mmol/l) with or without symptoms\], and level 3 (severe hypoglycemia with cognitive impairment, when external assistance is needed for recovery) \[[@CR47]\].

Overall, the new CGM devices are simpler, less expensive to use, and more accurate than older devices, and they require fewer or no daily calibrations against SMBG data \[[@CR62]\]. Sensor accuracy is assessed through metrics such as the precision absolute relative deviation (PARD), continuous glucose error--grid analysis (CG-EGA), and mean absolute relative difference (MARD) (Table [2](#Tab2){ref-type="table"}) \[[@CR45]--[@CR47]\]; a potentially overwhelming range of blood-glucose metrics can be provided by these systems \[[@CR63]\]. A study comparing the accuracy of CGM and that of a capillary blood glucose meter built into the reader in insulin-treated patients with T1D or T2D revealed a MARD of 11.4% for CGM with stability of readings over 14 days of use \[[@CR64]\]. A discrepancy of 10% between CGM and reference values has thus been proposed as sufficient to permit effective use of CGM without SMBG \[[@CR47], [@CR63]\], but this value is not based on outcome data. However, a study that used data on CGM, CSII, SMBG, and meals from patients with T1D, together with computer simulations, to determine the level of accuracy needed to forgo SMBG readings estimated an in silico MARD of 10% \[[@CR65]\].

The use of standalone CGM systems is supported by data from an open-label, randomized trial conducted in 226 adults with T1D and point-of-care HbA1c ≤ 9.0%. Compared with CGM plus SMBG, use of CGM alone had no negative effect on time in range, and time in hypoglycemia was not significantly different between groups. One severe hypoglycemic event occurred in the CGM plus SMBG group, but there were no reported hypoglycemic events in the CGM alone group \[[@CR66]\].

Standardized, easily understood data display formats are increasingly being used, such as the Ambulatory Glucose Profile (AGP) system \[[@CR17]\], which provides summary statistics, graphs showing 24-h glucose and daily glucose (pooled over multiple days), and insulin doses (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR17], [@CR67]\]. The AGP system can help primary care physicians and patients decide how best to increase the glucose time in range without increasing the risk of hypoglycemia \[[@CR57]\], since observed glucose excursions, for example, can be related to events such as the timing and content of meals, type of exercise, medications (e.g., prandial insulin), or periods of stress or illness \[[@CR68]\].Fig. 2Ambulatory glucose profile for use in CGM devices. *IQR* interquartile range, *CGM* continuous glucose monitoringFrom: <http://www.agpreport.org/agp/agpreports>

Several CGM devices are commercially available (Table [3](#Tab3){ref-type="table"}) \[[@CR69], [@CR70]\]. Unblinded, real-time CGM systems with hyperglycemia or hypoglycemia alerts may be particularly useful for patients with hypoglycemia unawareness \[[@CR71]\], whereas personal or professional 'flash' CGM systems may be attractive to other groups given their longer sensor life, ease of use, relatively low cost, and no need for calibration \[[@CR11]\].Table 3US FDA-approved CGM systemsSystemData typeSensor lifeCalibrationData direct to smart device?Low/high blood sugar warning?Medtronic iPro2 \[[@CR69]\]Blinded6 daysAt least 4 per dayNo; application available for patient to log eventsNoDexcom G4 PLATINUM \[[@CR69]\]Blinded or unblinded7 daysEvery 12 h (or when prompted)NoYesDexcom G5 Mobile^a^ \[[@CR69]\]Unblinded7 daysEvery 12 h (or when prompted)Yes; data can be shared remotelyYesDexcom G6 \[[@CR70]\]Unblinded10 daysNot neededYes; data can be shared remotelyYes (alarms can be customized)Abbott FreeStyle Libre Pro (flash) \[[@CR69]\]Blindedup to 14 daysNot neededNoNoAbbott FreeStyle Libre (flash)^a,\ b^ \[[@CR69]\]Unblinded10--14 daysNot neededYesNo; shows glucose trends^a^May be used to replace blood glucose measurement through fingersticks^b^Abbott Freestyle Libre 2, with optional real-time alarms, has recently secured CE mark in Europe

Possible Benefits of CGM {#Sec7}
------------------------

Several studies have comprehensively demonstrated the benefits of CGM in patients with T1D, who show consistently improved glycemic control with fewer hypoglycemic events \[[@CR72]--[@CR79]\]. In a trial conducted in 322 adults and children with well-controlled T1D (HbA1c = 7.0--10%) who were predominantly receiving CSII, CGM use resulted in a significant improvement in all glycemic measures, including HbA1c reduction, at 26 weeks. This reduction was significantly greater than that achieved with SMBG in patients aged \> 25 years (mean difference in change: − 0.53%; 95% confidence interval: − 0.71%, − 0.35%; *P* \< 0.001) \[[@CR72]\]. A subsequent analysis of the same group of patients showed that CGM significantly reduced HbA1c and time spent out of range (377 vs. 491 min/day; *P* = 0.003) and was associated with a numerical reduction in time spent in hypoglycemia compared with the control group (median 54 vs. 91 min/day; not statistically significant) \[[@CR73]\]. Data from the DIAMOND study showed that use of CGM (vs. usual care, which was SMBG ≥ 4 times daily) for 24 weeks resulted in a greater decrease in HbA1c (mean reduction from baseline: 1.0% vs. 0.4%; *P* \< 0.001) and a shorter duration of hypoglycemia (median duration of blood glucose \< 70 mg/dl: 43 min/day vs. 80 min/day; *P* = 0.002) \[[@CR76]\].

Other studies have assessed the effectiveness of CGM in helping individuals with impaired hypoglycemia awareness or history of severe hypoglycemia \[[@CR80]--[@CR82]\]. In a 24-week study, improvements in hypoglycemia awareness and reductions in the number of severe hypoglycemic events were similar whether subjects used SMBG or CGM or whether they were treated with multiple daily injections (MDIs) of insulin or CSII \[[@CR80]\]. Furthermore, in a 16-week study of patients with T1D and impaired awareness of hypoglycemia who received CSII or MDIs of insulin, CGM resulted in fewer severe hypoglycemic events (*P* = 0.003), more time in normoglycemia (*P* \< 0.0001), and less time in hypoglycemia (*P* \< 0.0001) vs. SMBG \[[@CR81]\]. A recent trial has shown that, in high-risk subjects with T1D treated with MDIs of insulin, the use of CGM reduced the incidence of hypoglycemic events by 72% (*P* \< 0.0001) compared with SMBG \[[@CR82]\].

CGM may also help elucidate patients' responses to different insulin formulations and other hypoglycemic agents. A study of patients with T1D treated with two concentrations of insulin glargine used CGM to evaluate several aspects of glycemic control. Patients were randomly assigned to inject insulin glargine 100 or 300 U/ml in the morning or the evening for 8 weeks and then in the evening (if previously morning) or morning (if previously evening) at the same dose for 8 more weeks. CGM revealed a 24-h glucose profile that was more consistent, with fewer glucose fluctuations, with insulin glargine 300 U/ml vs. the 100 U/ml preparation, regardless of time of injection. Patients using insulin glargine 300 U/ml also had fewer episodes of confirmed severe nocturnal hypoglycemia \[[@CR83]\]. In addition, the use of CGM in the investigational evaluation of a sodium-glucose co-transporter 2 inhibitor as adjunctive treatment in patients with T1D demonstrated the clinical value of the agent beyond HbA1c control through improvement of time in range \[[@CR84]\].

Although conflicting data exist, clinical trials have shown that use of CGM not only reduces HbA1c and hypoglycemia, but it may also attenuate the fear of hypoglycemia and diabetes-related stress and improve quality of life \[[@CR79], [@CR85]--[@CR88]\]. A real-world study of adults with T1D using CSII who started CGM showed decreased hospitalizations due to hypoglycemia and/or ketoacidosis and reduction in hospital stays and work absenteeism after 1 year \[[@CR89]\].

Data in T2D are more limited but nevertheless provide evidence of greater benefits of CGM over SMBG in glycemic control for patients receiving MDI of insulin \[[@CR77], [@CR90]\] or other regimens \[[@CR91], [@CR92]\]. In a 52-week randomized trial in patients with T2D treated with various regimens (except prandial insulin), the mean decline in HbA1c at 12 weeks was 1.0% (± 1.1%) with CGM for four 2-week cycles (2 weeks on, 1 week off) and 0.5% (± 0.8%) with SMBG (*P* = 0.006) \[[@CR91]\]. In the DIAMOND study, patients with T2D who received MDI of insulin showed a mean HbA1c reduction of 1.0% with CGM vs. 0.6% with usual care (adjusted difference: − 0.3%; *P* = 0.005); there were no meaningful differences in time spent in hypoglycemia or changes from baseline in insulin dose \[[@CR76]\]. Older adults (aged ≥ 60 years) with T1D or T2D in the DIAMOND study also had significantly greater reductions from baseline in HbA1c with CGM vs. SMBG (0.9 ± 0.7% vs. − 0.5 ± 0.7%, adjusted difference in mean change: − 0.4 ± 0.1%; *P* \< 0.001) \[[@CR93]\].

Recent data show the benefits of 'flash' CGM. Its use in two randomized clinical trials reduced the time spent in hypoglycemia by 38% in patients with well-controlled T1D \[[@CR94]\] and by 43% in insulin-treated adults (56% for those aged ≥ 65 years) with T2D \[[@CR95]\]. Both reductions were significantly greater than those seen with SMBG. A real-world study of patients with T1D or T2D showed greater reductions in HbA1c levels with 'flash' CGM vs. SMBG, with a more marked difference between groups in T1D \[[@CR96]\]. A recent large-scale (of more than 50,000 users), real-world study has further shown that the number of glucose checks using 'flash' glucose monitoring is inversely associated with time spent in hypoglycemia or hyperglycemia and positively correlated with time spent in euglycemia \[[@CR97]\]. However, the I HART CGM study showed that switching from 'flash' to real-time CGM has a greater favorable impact on hypoglycemia for adults with T1D at high risk of hypoglycemia (reduction in percentage time in hypoglycemia from 5% to 0.8%) \[[@CR98]\], indicating that 'flash' CGM would not be indicated for this specific patient population. In addition, a direct comparison of glucose concentration measured by 'flash' vs. CGM systems showed overall lower values for the 'flash' system compared with SMBG, with discrepancies between systems seen during hypoglycemia \[[@CR99]\]. This further highlights the need for frequent collection of glucose data to optimize glycemic control and minimize the risk of hypoglycemia.

There is also evidence on the clinical effectiveness of integrated CGM and insulin pump systems (sensor-augmented pump therapy) for the management of T1D. These systems warn of abnormal blood glucose levels so that the user can adjust the insulin infusion rate. More recent devices can automatically stop insulin delivery for up to 2 h (and then the insulin infusion basal rate is restored) if they predict a hypoglycemic episode. A systematic review showed that attainment of HbA1c \< 7% and improved quality of life at 6 months of follow-up were reported in a higher proportion of patients using integrated CSII plus CGM systems than in those using SMBG or CSII plus SMBG and MDI \[[@CR100]\].

It is important to note that the benefits of CGM were shown in clinical trials with treatment adherence rates higher than 85% \[[@CR73], [@CR76], [@CR101]\], but the compliance rate in patients with T1D in the real world is much lower (for example, only 8--17% for patients treated in specialty clinics) \[[@CR102], [@CR103]\]. In the US, CGM is least used by adolescents and young adults (\< 10%) and most used in adults aged 26--49 years (23%) \[[@CR104]\]. Barriers to routine CGM use include limited accuracy, inadequate reimbursement/cost, educational needs, patient annoyance due to frequent alarms, insertion pain, body image issues, and interference with daily life \[[@CR103]\].

Guidelines on the Use of CGM {#Sec8}
----------------------------

CGM recommendations by professional bodies vary and are more consistent for T1D than for T2D (Table [4](#Tab4){ref-type="table"}) \[[@CR8], [@CR47], [@CR67], [@CR105]\]; they are, in general, conservative. The broadest and most recent guidelines are those from an international panel of physicians, researchers, and experts in CGM technology, who recommend CGM alongside HbA1c monitoring to assess glycemic status and inform adjustments to therapy in all patients with T1D and in patients with T2D receiving intensive insulin therapy but not reaching targets, especially if hypoglycemia is problematic \[[@CR47]\].Table 4Current guidelines for the use of CGM in the management of patients with diabetesADA \[[@CR8]\]AACE/ACE \[[@CR66]\]Endocrine Society \[[@CR105]\]International consensus \[[@CR47]\]CGM in conjunction with intensive insulin regimens is a useful tool to lower HbA1c in adults with T1D who are not meeting glycemic targetsCGM may be a useful tool in those with hypoglycemia unawareness and/or frequent hypoglycemia episodesCGM is recommended for adult and pediatric patients with T1D (particularly for those with history of severe hypoglycemia and hypoglycemia unawareness) and to assist in the correction of hyperglycemia in patients not at goalNo recommendations in patients with T2D because of limited dataRT-CGM is recommended for adults with T1D (with HbA1c levels above target or with well-controlled glycemia) who are willing and able to use these devices on a nearly daily basisShort-term, intermittent use of RT-CGM is suggested for adult patients with T2D (not on prandial insulin) who have HbA~1c~ levels ≥ 7% and are willing and able to use the deviceCGM should be considered in conjunction with HbA1c monitoring for glycemic status assessment and therapy adjustment in all patients with T1D or T2D receiving intensive insulin therapy who are not attaining glucose targets, especially if the patient is experiencing problematic hypoglycemia*CGM* continuous glucose monitoring, *HbA1c* glycated hemoglobin A~1c~, *RT*-*CGM* real-time continuous glucose monitoring, *T1D* type 1 diabetes, *T2D* type 2 diabetes

Glycemic control should be assessed on the basis of key metrics provided by CGM, including glycemic variability, time in range, time above range (i.e., hyperglycemia), and time below range (i.e., hypoglycemia). These metrics should be obtained from 70 to 80% of all possible readings made during ≥ 14 days of CGM \[[@CR47]\].

Recent guidelines have highlighted the need to consider outcomes beyond HbA1c control, such as a standard time in range, as an endpoint in clinical trials \[[@CR53], [@CR106]\]. This is supported by advocacy groups and the US Food and Drug Administration \[[@CR107]\].

In general, despite mounting evidence of its effectiveness, only a small proportion of patients have access to CGM. This is mainly due to cost/reimbursement issues, an absence of specific guidelines on CGM use, and the complexity of the technology. Additional real-world cost-effectiveness data are needed to support routine use of CGM. Once technologic improvements produce easier-to-use devices with easy-to-understand data displays that are more cost effective than SMBG, CGM can be used alongside HbA1c monitoring to guide management strategies that better achieve optimal and stable glycemic control with a low risk of hypoglycemia \[[@CR17]\].

Cost Effectiveness of CGM Devices {#Sec9}
---------------------------------

Overall, CGM is more effective than SMBG but is associated with higher costs \[[@CR100], [@CR108]\]. A meta-analysis showed that the most cost-effective use of CGM is probably for people with T1D and continued poor glycemic control despite intensified insulin therapy \[[@CR109]\]. A cost-effectiveness analysis of data from the DIAMOND study showed that, in adults with T1D and elevated HbA1c (≥ 7.5%), CGM increased costs compared with SMBG but was a lifetime cost-effective intervention when clinical benefits (HbA1c reduction, daily strip use, and frequency of non-severe hypoglycemia) were taken into account \[[@CR110]\]. Similarly, for high-risk patients with T1D and impaired hypoglycemia awareness, the economic impact of CGM is counteracted by lower hypoglycemia-related costs, reduced SMBG strip use, avoidance of HbA1c-related complications, and reduced insulin pump use \[[@CR111]\]. CGM is also known to be cost effective in the management of patients with T2D not treated with prandial insulin \[[@CR112]\].

Future of CMG {#Sec10}
-------------

Closed-loop systems ('artificial pancreas'), which consist of a CGM monitor and an insulin pump that delivers insulin through a standardized algorithm, have recently emerged as a means to attain glucose control in T1D. A systematic review and meta-analysis of randomized studies evaluating artificial pancreas systems in adult and pediatric patients with T1D in the outpatient setting showed improved glucose control, with higher time in target, compared with conventional pumps \[[@CR113]\]. While these systems ensure a smooth glucose profile overnight with low risk of hypoglycemia, user input is usually required during meal times. Some devices are exploring fully automated options, but these run higher risk of hypoglycemia vs. systems requiring input of information on meal activity \[[@CR114]\].

Conclusions {#Sec11}
===========

Although HbA1c remains the cornerstone of glycemic status monitoring, even 'good' glycemic control may include substantial blood glucose fluctuations and excursions into hyperglycemia and hypoglycemia, both of which are associated with short- and long-term complications. Hypoglycemia in particular represents a key challenge to safely achieving and maintaining glycemic targets.

SMBG gives an indication of glycemic variability, but each measurement provides only a 'snapshot' of blood glucose levels, and glucose excursions may be missed. The need for repeated daily fingersticks limits its usefulness, and 'forgotten' logbooks or meters and incomplete or inaccurate SMBG data may leave physicians without the information they need to optimize their patients' glycemic control.

CGM has demonstrated the importance of glycemic variability and its association with hypoglycemia independently of HbA1c values. In both clinical trials and in the real-world setting, CGM was effective in reducing glucose levels and hypoglycemia as well as in attenuating diabetes stress and improving quality of life vs. usual care, but treatment compliance is key for effectiveness. Modern, easy-to-use CGM systems, particularly devices that do not require regular calibration, and simplified data displays could overcome many of the limitations of HbA1c monitoring and SMBG.

In summary, CGM provides physicians with the ability to improve on conventional methods of blood glucose monitoring and offers valuable additional data to inform better and safer decision-making.
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